



December 19, 2024

To Whom It May Concern

Company: Teijin Limited
 Representative: Akimoto Uchikawa, President and CEO
 Stock code: 3401 (Prime Market, Tokyo Stock Exchange)
 Contact: Tetsuji Mikami, Deputy General Manager,
 Corporate Communication Department
 (Responsible for Investor Relations)
 TEL: +81-3-3506-4395

Notice on Change in an Equity Method Affiliated Company (Share Transfer)

Teijin Limited (hereinafter, the "Company") hereby announces that it has resolved today to transfer the shares of Esteve Teijin Healthcare, S. L. (hereinafter, "ETH") to Oximesa S.L.U. as detailed below.

1. Reason for the share transfer

As a part of building a global platform for its home healthcare businesses, the Company launched a home healthcare service provision business in Spain in February 2009 through ETH, a joint venture with Corporacion Quimico Farmaceutica Esteve S.A. (hereinafter, "Esteve"), aiming to establish a business base in Europe. Since then, ETH has expanded its business mainly by winning public tenders in several regions in Spain. After Esteve communicated to Teijin the intention of its group of companies to focus its activities in healthcare areas other than home respiratory business, the Company and Esteve considered that the transfer of the shares was the best option for further growth of the Company and of ETH. The decision of the Company has been taken considering that the Spanish business, for the Company, has been developed based on the relationship with Esteve and on Esteve's robust business position in Spain.

2. Outline of ETH

(1) Name	Esteve Teijin Healthcare, S.L.	
(2) Location	Passeig del Ferrocarril, 369, P. I. Camí Ral, 08860 Castelldefels, Barcelona, Spain	
(3) Name and title of representative	Carlos Fina, Chief Executive Officer	
(4) Line of business	Home healthcare service provision business	
(5) Capital	15.5 million Euro (as of December 31,2023)	
(6) Establishment	February 2009	
(7) Major shareholder(s) and ownership percentage	Teijin Holdings Europe B.V. 50.00 % Corporacion Quimico Farmaceutica Esteve S.A. 50.00 %	
(8) Relationship between the Company and ETH	Capital Relationship	The company holds 50.00% stake through a subsidiary
	Personnel Relationship	None
	Business Relationship	None
(9) Operating results and financial status of ETH for the last three years		

Fiscal year	Ended December 2021	Ended December 2022	Ended December 2023
Net assets	8 million euro (1,095 million yen)	12 million euro (1,644 million yen)	14 million euro (2,146 million yen)
Total assets	47 million euro (6,177 million yen)	47 million euro (6,711 million yen)	61 million euro (9,631 million yen)
Net sales	32 million euro (4,123 million yen)	33 million euro (4,501 million yen)	37 million euro (5,573 million yen)
Operating income	2 million euro (217 million yen)	2 million euro (321 million yen)	1 million euro (212 million yen)
Ordinary income	2 million euro (199 million yen)	2 million euro (282 million yen)	1 million euro (107 million yen)
Net income	1 million euro (191 million yen)	3 million euro (443 million yen)	2 million euro (313 million yen)

Note: The exchange rates used for conversion were as follows:

<Net assets, total assets, assets, and liabilities>

FY ended December 2021: 1 euro = 137 yen, FY ended December 2022: 1 euro = 146 yen

FY ended December 2023: 1 euro = 163 yen

<Net sales, operating income, ordinary income, profit>

FY ended December 2021: 1 euro = 131 yen, FY ended December 2022: 1 euro = 141 yen

FY ended December 2023: 1 euro = 157 yen

3. Outline of the Transferee

(1) Name	Oximesa S.L.U.	
(2) Location	Calle Orense 11, 28020 Madrid, Spain	
(3) Name and title of representative	Justin Corcho Maters & Jorge Ramon Huertas Colomina, (Joint Directors)	
(4) Line of business	Home healthcare service provision business	
(5) Capital	342 thousand Euro (as of March 31,2024)	
(6) Establishment	November 7, 1975	
(7) Net Assets	46.5 million Euro (as of March 31,2024)	
(8) Total Assets	77.4 million Euro (as of March 31,2024)	
(9) Major shareholder(s) and ownership percentage	Nippon Gases Euro-Holding S.L.U. (Note 1) 100.00%	
(10) Relationship between the Company	Capital relationship	None
	Personnel relationship	None
	Business relationship	None
	Status as a related party	None

Note 1: Nippon Sanso Holdings Corporation (NSHD) indirectly holds 100.00% of issued shares of Oximesa S.L.U. through Nippon Gases Euro-Holding S.L.U..

4. Outline of the share transfer

Number of shares owned before the Transactions	17,850 shares (Number of voting rights: 17,850) (Ownership ratio of voting rights: 50.00%)
Number of shares to be transferred through the Transactions	17,850 shares (Number of voting rights: 17,850) (Ownership ratio of voting rights: 50.00%)

Transfer price	Approx. 62 million euro (9,920 million Yen (Note 2))
Number of shares owned after the Transactions	0 shares (Number of voting rights: 0) (Ownership ratio of voting rights: 0.00%)

Note 2: 1 euro = 160 yen

5. Timeline

(1)	Resolution by the Company	December 19 , 2024
(2)	Signing of share transfer agreement	December 19 , 2024
(3)	Share transfer execution	Around later March 2025 (tentative)

6. Accounting overview

Due to the share transfer, we expect to record a gain on sale of stock of subsidiaries and affiliates approximately 7.0 billion yen in our consolidated financial results for the fiscal year ending March 2025. We will disclose any significant changes that may occur before the share transfer as quickly as possible.

7. Financial outlook

The impact of the above was taken into consideration in our consolidated earnings forecast for the fiscal year ending March 31, 2025, which was announced on November 7, 2024.

- End -